#Bcl6 inhibition destabilizes #TregCells by reducing H3K4me3, enhancing #AntiTumor immunity, delaying #HeadandNeckSquamousCellCarcinoma progression, and synergizing with immune checkpoint therapy, highlighting Bcl6 as a promising target.

#OpenAccess: doi.org/10.1016/j.ge...

Inhibition of Bcl-6 Expression Ameliorates Asthmatic Characteristics in Mice

Repressing #Bcl6 in an asthmatic mouse model disrupts #Tfhcell differentiation and B-cell responses, reduces #IgE levels in #serum and BALF & alleviates #AirwayInflammation, and highlights Bcl-6–Tfh signaling as a potential therapeutic target in #asthma.

Read: doi.org/10.1007/s115...

Targeting Immune Mechanisms in Myocardial Infarction – From Bioinformatic Discovery to Therapeutic Translation This editorial explores immune mechanisms in myocardial infarction, spotlighting S100A12 and BCL6 as key biomarkers driving next-gen precision cardiology.

This editorial highlights the emerging role of immune regulation in MI, emphasizing key genes #S100A12 & #BCL6 as novel diagnostic & therapeutic targets, & showcasing innovative #nanodelivery, & cell-based strategies advancing #PrecisionCardiology.

#OpenAccess: cvia-journal.org/immune-myoca...

This study identifies #BCL6 suppression as a promising strategy to reduce #Tfhcell differentiation, attenuate #IgE secretion, and mitigate #AirwayInflammation, thereby highlighting its therapeutic potential in #Asthma. #medsky

Read more: link.springer.com/article/10.1...

Comprehensive Bioinformatics Method to Explore Immune-Related Genes in the Pathogenesis of Myocardial Infarction Comprehensive bioinformatics reveals Immune-related genes changes in myocardial infarction, identifying promising diagnostic and therapeutic targets.

This comprehensive study integrates multi-dataset #bioinformatics, #immune infiltration profiling & functional validation to reveal S100A12 & #BCL6 as key immune-related #biomarkers & #TherapeuticTargets for early #MyocardialInfarction (MI) detection & intervention.
#OpenAccess: tinyurl.com/ymzxo6sm

Selectively targeting BCL6 using a small-molecule inhibitor is a potential therapeutic strategy for glioblastoma

#BCL6 is a lynchpin in #GBM and YK01, a novel small-molecule inhibitor of BCL6, has an excellent anti-GBM bioactivity, promotes #apoptosis, inhibits growth of GBM cells, and in combination with #temozolomide suppresses the growth & #metastasis of tumors. #medksy

#OpenAccess: buff.ly/kjR2IlU

Bcl6 controls the stability and suppressive function of regulatory T cells in head and neck squamous cell carcinoma

#Bcl6 plays a pivotal role in maintaining the lineage stability and suppressive function of Treg cells during #HeadandNeckSquamousCellCarcinoma and therefore can be exploited as a promising therapeutic target for HNSCC treatment.

#OpenAccess: https://buff.ly/40czJ5J